Onconetix, Inc.: KEYSTONE CAPITAL PARTNERS, LLC amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Keystone Capital Partners, LLC amended its Schedule 13G stake filing for Onconetix, Inc., disclosing its updated beneficial ownership position in the biotech company under SEC accession 0001213900-26-116262. The filing reflects a change to the investor's previously reported holdings, though the amendment's specific share count and percentage were not detailed in the headline disclosure. Schedule 13G amendments are typically watched for signals about passive investors' conviction in small-cap names like Onconetix. Investors will look to the full filing for the exact share total and any change in voting authority.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Onconetix, Inc., Keystone Capital Partners, LLC